Pfenex, U.S. Department of Health and Human Services infectious news

Pfenex said HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded the company a five-year contract with a total potential value of $143.5 million to develop Px563L, a recombinant protective antigen (rPA) anthrax vaccine.

The contract includes an initial $15.9 million to fund manufacturing of Px563L and the first Phase Ia trial of the candidate during a 30-month base period. Pfenex expects to begin the study this year. ...